Oral Abstract Session A: Cancers of the Esophagus and Stomach
Robert Shen, MD—Chair, Mayo Clinic & Daniela Molena, MD—Chair, Memorial Sloan Kettering Cancer Center
Abstract 62: First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
First Author: Yelena Yuriy Janjigian, MD
CONCLUSION: Updated survival, correlative studies and 89Zr-trastuzumab PET imaging will be presented. These promising preliminary safety and efficacy results led to initiation of a definitive phase III Keynote 811 trial. Clinical trial information: NCT02954536
Clinical trial information: NCT02564263
Abstract 3: Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS).
First Author: David H. Ilson, MD, PhD
CONCLUSION:• FTD/TPI prolonged survival versus placebo regardless of gastrectomy • HematologicAEs such as neutropenia/leukopenia may have been somewhat more frequent among FTD/TPl-treated patients with gastrectomy than in the overall population - This did not result in more treatment discontinuations • Exposure to FTD/TPI was similar between patients with gastrectomy and those in the overall population • FTD/TPI is an effective treatment option with a manageable safety profile for patients with mGC regardless of prior gastrectomy.
Clinical trial information: NCT02500043
Abstract 4: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
First Author: Manish A. Shah, MD, FASCO
CONCLUSION:• Addition of ADX to mFOLFOX6 did not improve OS in patients with untreated HER2- gastric or GEJ adenocarcinoma • There were no meaningful differences in the safety profile of the ADX vs placebo groups • The apparent increased activity of the combination of mFOLFOX6 + ADX in patients aged >65 needs further study and correlative work • ADX + immunotherapy has been examined and is presented at this meeting (see Posters 75, 118, and 148) Clinical trial information: NCT02545504